Magnus Petersson

Also affiliated with Harvard University, AstraZeneca (Brazil), AstraZeneca (Sweden)

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial”.

Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial

Circulation(2022)10.1161/circulationaha.122.061754

N/A

4.2DataRank · unranked

152 citations

Pardeep S. Jhund, Jan Bělohlávek, Rudolf A. de Boer, Chern‐En Chiang, Akshay S. Desai +22 more

Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

JAMA Cardiology(2022)10.1001/jamacardio.2022.3750

N/A

2.9DataRank · unranked

67 citations

Brian Claggett, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi +12 more

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

Nature Medicine(2022)10.1038/s41591-022-02102-9

N/A

1.7DataRank · unranked

67 citations

James C. Fang, Akshay S. Desai, Pardeep S. Jhund, Brian Claggett, Muthiah Vaduganathan +19 more

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

European Heart Journal(2023)10.1093/eurheartj/ehad283

N/A

1.6DataRank · unranked

56 citations

Muthiah Vaduganathan, Brian Claggett, Orly Vardeny, Akshay S. Desai, Pardeep S. Jhund +15 more

Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

JACC Heart Failure(2022)10.1016/j.jchf.2022.08.007

N/A

1.5DataRank · unranked

50 citations

Muthiah Vaduganathan, Brian Claggett, Zi Michael Miao, Pardeep S. Jhund, Rudolf A. de Boer +13 more

Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial

Circulation(2023)10.1161/circulationaha.123.066506

N/A

1.3DataRank · unranked

36 citations

Muthiah Vaduganathan, Brian Claggett, Jonathan W. Cunningham, Kieran F. Docherty, Akshay S. Desai +13 more

Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial

The Lancet Diabetes & Endocrinology(2022)10.1016/s2213-8587(22)00308-4

N/A

1.2DataRank · unranked

41 citations

Brian Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund, Rudolf A. de Boer +14 more

Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

JAMA Cardiology(2023)10.1001/jamacardio.2023.4664

N/A

1.0DataRank · unranked

38 citations

Brian Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund, Orly Vardeny +17 more

Effect of Dapagliflozin on Health Status and Quality of Life Across the Spectrum of Ejection Fraction: Participant-Level Pooled Analysis from the DAPA-HF and DELIVER Trials

European Journal of Heart Failure(2023)10.1002/ejhf.2909

N/A

1.0DataRank · unranked

22 citations

Mikhail Kosiborod, Muthiah Vaduganathan, Brian Claggett, Zi Michael Miao, Ian J. Kulac +13 more

Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

Circulation(2023)10.1161/circulationaha.123.065254

N/A

0.805DataRank · unranked

21 citations

Muthiah Vaduganathan, Senthil Selvaraj, Brian Claggett, Zi Michael Miao, Akshay S. Desai +13 more

Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

JAMA Cardiology(2023)10.1001/jamacardio.2023.1342

N/A

0.671DataRank · unranked

13 citations

Alvin Chandra, Mikhail Kosiborod, Brian Claggett, Akshay S. Desai, Pardeep S. Jhund +17 more

Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial

Circulation(2023)10.1161/circulationaha.122.062918

N/A

0.405DataRank · unranked

7 citations

Karola Jering, C. Jan Willem Borleffs, Rudolf A. de Boer, Brian Claggett, Akshay S. Desai +15 more

Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan

European Journal of Heart Failure(2022)10.1002/ejhf.2722

N/A

0DataRank · unranked

34 citations

Jawad H. Butt, Toru Kondo, Karola Jering, Kieran F. Docherty, Pardeep S. Jhund +16 more

Dapagliflozin in Patients with Heart Failure and Previous Myocardial Infarction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER

European Journal of Heart Failure(2024)10.1002/ejhf.3184

N/A

0DataRank · unranked

11 citations

Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Alberto Foà, Akshay S. Desai +17 more

Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease

European Heart Journal(2024)10.1093/eurheartj/ehae780

N/A

0DataRank · unranked

8 citations

Mats Christian Højbjerg Lassen, Brian Claggett, Zi Michael Miao, Silvio E. Inzucchi, Kieran F. Docherty +16 more